PRAZOSIN HYDROCHLORIDE - Generic Drug Details

What are the generic sources for prazosin hydrochloride and what is the scope of patent protection?

Prazosin hydrochloride is the generic ingredient in three branded drugs marketed by Pfizer, Alembic, Am Therap, Ani Pharms, Appco, Aurobindo Pharma Ltd, Dava Pharms Inc, Granules, Lannett Co Inc, Mankind Pharma, MSN, Mylan, Novitium Pharma, Purepac Pharm, Teva Pharms, and Watson Labs, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for prazosin hydrochloride. Thirty-two suppliers are listed for this compound.

Summary for PRAZOSIN HYDROCHLORIDE

US Patents:	0
Tradenames:	3
Applicants:	16
NDAs:	25
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	32
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	70
What excipients (inactive ingredients) are in PRAZOSIN HYDROCHLORIDE?	PRAZOSIN HYDROCHLORIDE excipients list
DailyMed Link:	PRAZOSIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PRAZOSIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Wisconsin, Madison	PHASE2
National Institute of Neurological Disorders and Stroke (NINDS)	PHASE2
Kinnov Therapeutics	Phase 1

See all PRAZOSIN HYDROCHLORIDE clinical trials

Pharmacology for PRAZOSIN HYDROCHLORIDE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for PRAZOSIN HYDROCHLORIDE

Adrenergic alpha-1 Receptor Antagonists

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for PRAZOSIN HYDROCHLORIDE

C02CA	Alpha-adrenoreceptor antagonists
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for PRAZOSIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Appco	PRAZOSIN HYDROCHLORIDE	prazosin hydrochloride	CAPSULE;ORAL	213406-001	Oct 21, 2022	AB	RX	No	No
Appco	PRAZOSIN HYDROCHLORIDE	prazosin hydrochloride	CAPSULE;ORAL	213406-003	Oct 21, 2022	AB	RX	No	No
Granules	PRAZOSIN HYDROCHLORIDE	prazosin hydrochloride	CAPSULE;ORAL	214608-003	Dec 23, 2021	AB	RX	No	No
Ani Pharms	PRAZOSIN HYDROCHLORIDE	prazosin hydrochloride	CAPSULE;ORAL	072577-001	May 16, 1989		DISCN	No	No
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-002	Jan 29, 1992		DISCN	No	No

Expired US Patents for PRAZOSIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-002	Jan 29, 1992	5,082,668
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	3,663,706
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	4,783,337
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-002	Jan 29, 1992	4,765,989
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	4,327,725

Market Dynamics and Financial Trajectory for Prazosin Hydrochloride

Last updated: July 27, 2025

Introduction

Prazosin hydrochloride, a selective alpha-1 adrenergic receptor antagonist, was initially developed as an antihypertensive agent. Its pharmacological profile extends beyond blood pressure regulation, encompassing off-label uses such as trauma-related nightmares in PTSD and benign prostatic hyperplasia (BPH). Despite its longstanding generic availability, recent shifts in therapeutic utilization, market forces, and regulatory developments influence its financial horizon. This article assesses the evolving market dynamics and projected financial trajectory of prazosin hydrochloride within the pharmaceutical landscape.

Pharmacological Profile and Therapeutic Applications

Originally introduced in the 1980s, prazosin functions as an antagonist targeting alpha-1 adrenergic receptors, leading to vasodilation and blood pressure reduction [1]. Its primary approval pertains to hypertension management, but clinicians increasingly leverage its off-label uses:

• Post-Traumatic Stress Disorder (PTSD)–related nightmares (off-label)
• Benign prostatic hyperplasia (BPH)
• Raynaud’s phenomenon

Cumulatively, these applications have fueled niche-market growth, though not to the extent of blockbuster drugs in the class.

Market Size and Demand Drivers

Generic Market Penetration

As a generic, prazosin hydrochloride faces intense price competition; no recent patent protections restrict manufacturing. According to IQVIA data, the global antihypertensive drug market exceeds $20 billion annually, with alpha-blockers accounting for roughly 3-5%, primarily driven by terazosin, tamsulosin, and doxazosin [2]. Prazosin constitutes a fraction of this segment, with limited market share owing to emerging alternatives.

Off-Label and Specialized Uses

Off-label pharmacotherapy, notably for PTSD, offers asymmetric demand. While the VA and military hospitals report routine off-label prescriptions, these are concentrated geographically and institutionally, resulting in modest sales volumes. Furthermore, regulatory agencies do not oversee off-label prescribing but influence market potential indirectly. The BPH indication, increasingly served by tamsulosin and other uroselective alpha blockers, diminishes prazosin’s share in that domain.

Competitive Landscape

Major competitors, including tamsulosin (Flomax), alfuzosin, and silodosin, benefit from improved selectivity and tolerability profiles, shrinking prazosin’s market attractiveness [3].

In the antihypertensive segment, prazosin faces competition from ACE inhibitors, ARBs, calcium channel blockers, and diuretics, many of which boast better side effect profiles and patent protections, limiting generic pricing power and volume growth.

Regulatory Environment and Patent Landscape

Prazosin hydrochloride, now generically available, is not under patent protection. Regulatory agencies, such as the FDA, classify it as an approved generic antihypertensive, easing entry for manufacturers. The lack of patent exclusivity constrains pricing power and limits investment in formulation innovations.

However, recent regulatory support for reformulating existing drugs with improved delivery systems (e.g., extended-release formulations) could provide renewed commercialization opportunities if manufacturers pursue such routes.

Market Challenges and Opportunities

Challenges

• Price Competition: The generic status precipitates low per-unit prices, constraining margins.
• Market Saturation: Ubiquity of generic availability caps sales growth.
• Emerging Alternatives: Safer, more tolerable drugs for hypertension and BPH erode prazosin’s niche.

Opportunities

• Off-label Expansion: Growing awareness of prazosin’s benefits for PTSD complicates traditional prescribing margins but could sustain demand in specialty niches.
• Formulation Innovations: Developing extended-release or combination formulations may command premium pricing.
• Regional Market Expansion: Emerging markets with less saturation, such as parts of Asia and Latin America, offer growth potential.

Financial Trajectory Analysis

Given current market conditions, prazosin hydrochloride's financial outlook appears modest and stable rather than explosive:

• Revenue Projections: Annual global sales are estimated in the range of $50–100 million predominantly from generic manufacturers (based on market shares and annual prescriptions).
• Margins: Gross margins are low due to high competition, with net margins often below 10% for producers.
• Growth Potential: Limited unless novel formulations or new indications stimulate demand, which remains uncertain in the short term.
• Market Risks: Patent expirations, drug recalls, or regulatory restrictions could significantly impact financial prospects.

Impact of Emerging Trends

• Personalized Medicine: Identifying patient subgroups more responsive to prazosin could elevate demand.
• Digital Health and Monitoring: Integration with telehealth protocols for PTSD management might expand off-label use.
• Regulatory Dynamics: Approval of new indications or formulations could modify the revenue landscape.

Conclusion

Prazosin hydrochloride operates within a highly commoditized segment characterized by intense price competition and limited innovation. Its financial trajectory remains stable but not growth-oriented unless manufacturers leverage niche uses or develop improved formulations. The primary market drivers—generic availability, off-label uses, and regional expansion—dictate a conservative revenue outlook, emphasizing efficiency and strategic positioning for stakeholders.

---

Key Takeaways

• The global prazosin hydrochloride market is constrained by generic competition, limiting pricing power and growth.
• Off-label uses for PTSD offer niche demand but lack significant commercial traction.
• Competitive drugs with better tolerability, notably tamsulosin, threaten prazosin’s market share, especially for BPH.
• Opportunities exist in reformulation and regional expansion but require investment and strategic focus.
• Long-term financial success hinges on innovation and exploitation of unmet clinical needs in specialized markets.

---

FAQs

Q1: How does the off-label use of prazosin for PTSD influence its market?
Off-label prescriptions for PTSD-related nightmares sustain niche demand but are limited geographically and institutionally, contributing modest revenue without regulatory exclusivity.

Q2: Are there opportunities for branded formulations of prazosin?
Yes, developing extended-release or combination formulations could justify premium pricing, but such opportunities demand regulatory approval and market acceptance.

Q3: What are the primary competitive threats to prazosin hydrochloride?
More selective alpha-blockers like tamsulosin for BPH and newer antihypertensives with better tolerability and patent protection reduce prazosin’s appeal.

Q4: How does the patent landscape affect prazosin’s market?
Absence of patent protections results in low barriers to entry, intense price competition, and limited margin potential for manufacturers.

Q5: Could emerging markets become significant revenue sources for prazosin?
Potentially, as markets with less generic saturation and different prescribing practices may offer growth opportunities, contingent on regional healthcare policies and access.

---

Sources:
[1] EPAR - Prazosin: Summary of Product Characteristics. European Medicines Agency.
[2] IQVIA PharmaScope Data (2022).
[3] U.S. FDA Orange Book, 2023.